Manuel Baca

TL;DR: It appears that the SOCS proteins may act as adaptor molecules that target activated cell signaling proteins to the protein degradation pathway, analogous to the family of F-box-containing proteins.

TL;DR: In this article, humanized and variant anti-VEGF antibodies and various uses therefor are disclosed, which have strong binding affinities for VEGF; inhibit VEGFs-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.

TL;DR: Data suggest that the mechanism by which SOCS-3 inhibited signaling in cells transfected with a chimeric receptor containing the wild-type gp130 intracellular domain depends on recruitment to the phosphorylated gp130 receptor, and that some of the negative regulatory roles previously attributed to the tyrosine phosphatase SHP-2 might in fact be caused by the action of SOCS.

TL;DR: Although inhibition of signaling by SOCs‐1 and SOCS‐3 requires both the SH2 and N‐terminal domains, their mechanisms of action appear to be biochemically different.

TL;DR: This method provides a general means of rapidly selecting framework mutations that improve the binding of humanized antibodies to their cognate antigens and may prove an attractive alternative to current methods of framework optimization based on cycles of site-directed mutagenesis.